Deprecated: Creation of dynamic property PL_VBP_License::$version is deprecated in /var/www/healingmaps.imarkdev.com/wp-content/plugins/video-background-pro/license-page.php on line 92

Deprecated: Creation of dynamic property Vidbg_WPBakery::$vc_row_atts is deprecated in /var/www/healingmaps.imarkdev.com/wp-content/plugins/video-background-pro/inc/classes/vidbg_wpbakery.php on line 49
ketamine therapy - Page 2 of 27 - HealingMaps

A Federal Report Just Told States to Prepare for Psychedelic Approval. Ketamine Clinics Are the Template

SAMHSA told states to build the budget, licensing, and oversight machinery for psychedelic therapy before the FDA approves anything. Ketamine is not named once.

Read More

Three Infusions in Twelve Weeks: A Toronto Pain Trial Ran a Very Different Protocol

A Toronto trial paired ketamine with structured therapy for chronic nerve pain. It used three infusions over twelve weeks, not six over three.

Read More

4 Best Ketamine Clinics in Tacoma, WA (2026) — Verified & Reviewed

Most of Tacoma’s ketamine infrastructure sits on a single street: the region’s most experienced infusion practice and its widest-menu interventional psychiatry clinic both operate on South Union Avenue, four blocks apart. The four providers ranked here hold verified listings in the HealingMaps Washington directory, and that per-clinic detail drives the rankings; the pricing context around […]

Read More

4 Best Ketamine Clinics in Provo (2026) — Verified & Reviewed

A ketamine patient in Provo is choosing among three care models more than among neighborhoods: a national interventional psychiatry office downtown, homegrown Utah County programs built around ketamine-assisted psychotherapy, and a flat-rate infusion clinic thirty minutes up I-15. Every provider ranked below is documented in a verified HealingMaps directory listing, while the surrounding cost context […]

Read More

IV Ketamine Could Get Its First FDA Psychiatric Indication. Here Is What Would Actually Change

Last reviewed and updated: August 13, 2026. Headlines about the FDA and ketamine will multiply this year. Most operators will read them wrong. Some describe a generic manufacturing application. One concerns NRX-100, a specific IV ketamine product pursuing a psychiatric indication. That program could change how clinics approach coverage, marketing and protocols. Knowing which is […]

Read More

England Has a Recreational Ketamine Crisis. Here Is How American Clinics Keep It From Happening Here

In one Manchester treatment cohort, 64 percent of the people being treated for ketamine problems were under 18. Forty two percent were between 13 and 16. That is what a recreational ketamine crisis looks like once it has fully arrived, and England is living in one. America is not, and the reason has less to […]

Read More

Ketamine Raised Morning Cortisol in a New Trial. Here Is What That Might Mean

A randomized trial found higher morning cortisol 24 hours after ketamine. Bigger rises tracked with less suicidal thinking, though more data needed.

Read More

Before a Buyer Calls: Getting Your Ketamine Clinic Ready for Acquisition

The first call rarely announces itself as an offer. It sounds like a compliment, someone building a platform in your region admires what you have built and wonders whether you have ever thought about partners. What happens next depends almost entirely on work you either did or did not do during the two years before […]

Read More

Review Finds Evidence for Ketamine Assisted Psychotherapy Remains Limited

Ketamine clinics often pair medication with therapy, preparation, or integration. A new review asks whether psychotherapy adds measurable benefit for adults with depression. The answer remains uncertain. Researchers found widespread clinical use, but far less rigorous evidence than the popularity of these programs may suggest. New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign […]

Read More

The First Ketamine Clinic Roll Ups Failed. The Next Wave Will Be Different

On July 16, Eli Lilly agreed to pay up to $3.8 billion for AtaiBeckley and its late stage psychedelic depression program. A week earlier, Johnson & Johnson reported $584 million in quarterly Spravato sales, up 40 percent in a year. AbbVie has already committed up to $1.2 billion for a psychedelic depression drug from Gilgamesh. […]

Read More